Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China To Revise Law On Patent Abuse

This article was originally published in PharmAsia News

Executive Summary

A draft of China's revised patent law will be submitted to the Standing Committee of the National People's Congress for review on Aug. 25. A key point of the revision is the restriction of patent rights abuse. The draft explains that in situations where public health is threatened by epidemics or infectious diseases, the patent administrative department under State Council can decide on imposing a mandatory licensing system for drugs to guarantee adequate supply. Bolar Exception rules are also included (PharmAsia News, July 22, 2008). If passed, the new law will benefit local firms, which are increasingly facing pharmaceutical MNC charges on patent infringement. (Click here for more - Chinese Language)

You may also be interested in...



Insider Analysis From Jones Day: What Does the 3rd Amendment to China’s Patent Law Mean to Pharmaceutical Companies?

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel